Key facts
| Price (PPV) | 239 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbesartanhydrchlorothiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA04 |
| Manufacturer | SANOFI AVENTIS MAROC |
| Presentation | Boîte de 28 |
| Nature | Médicament |
| Hospital price | 150 MAD |
| Data collected on | 9/8/2026 |
Indications
COAPROVEL® est indiqué dans le traitement de l’hypertension artérielle essentielle. Cette association à dose fixe est indiquée chez les patients adultes dont la pression artérielle est insuffisamment contrôlée par l’Irbésartan seul ou l’Hydrochlorothiazide seul.
Find an open pharmacy
On-call pharmacies near you
About Coaprovel 300 mg / 12.5 mg
Coaprovel 300 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by SANOFI AVENTIS MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Coaprovel 300 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Coaprovel 300 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.